{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:58:38Z","timestamp":1771916318398,"version":"3.50.1"},"reference-count":22,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2017,5,1]]},"DOI":"10.1188\/17.onf.296-301","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T08:46:20Z","timestamp":1499071580000},"page":"296-301","source":"Crossref","is-referenced-by-count":17,"title":["Vaginal Testosterone for Management of Aromatase Inhibitor\u2013Related Sexual\n            Dysfunction: An Integrative Review"],"prefix":"10.1188","volume":"44","author":[{"given":"Emily","family":"Lemke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Dains","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2017,5,1]]},"reference":[{"key":"1","unstructured":"American Cancer Society. (2015). Breast cancer facts and\n              figures, 2015\u20132016. Retrieved from\n              https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-..."},{"key":"2","doi-asserted-by":"crossref","unstructured":"Barton, D.L., Wender, D.B., Sloan, J.A., Dalton, R.J., Balcueva,\n              E.P., Atherton, P.J., . . . Loprinzi, C.L. (2007). Randomized controlled trial to\n              evaluate transdermal testosterone in female cancer survivors with decreased libido;\n              North Central Cancer Treatment Group protocol N02C3. Journal of the National Cancer\n              Institute, 99, 672\u2013679. doi:10.1093\/jnci\/djk149","DOI":"10.1093\/jnci\/djk149"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bartula, I., & Sherman, K.A. (2015). The Female Sexual\n              Functioning Index (FSFI): Evaluation of acceptability, reliability, and validity in\n              women with breast cancer. Supportive Care in Cancer, 23, 2633\u20132641.\n              doi:10.1007\/s00520-015-2623-y","DOI":"10.1007\/s00520-015-2623-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Baser, R.E., Li, Y., & Carter, J. (2012). Psychometric\n              validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer,\n              118, 4606\u20134618. doi:10.1002\/cncr.26739","DOI":"10.1002\/cncr.26739"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Cuzick, J., Sestak, I., Forbes, J.F., Dowsett, M., Knox, J.,\n              Cawthorn, S., . . . Howell, A. (2014). Anastrozole for prevention of breast cancer in\n              high-risk postmenopausal women (IBIS-II): An international, double-blind, randomised\n              placebo-controlled trial. Lancet, 383, 1041\u20131048. doi:10.1016\/s0140-6736(13)62292-8","DOI":"10.1016\/S0140-6736(13)62292-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Dahir, M., & Travers-Gustafson, D. (2014). Breast cancer,\n              aromatase inhibitor therapy, and sexual functioning: A pilot study of the effects of\n              vaginal testosterone therapy. Sexual Medicine, 2, 8\u201315. doi:10.1002\/sm2.22","DOI":"10.1002\/sm2.22"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Davis, S.R., Moreau, M., Kroll, R., Bouchard, C., Panay, N.,\n              Gass, M., . . . Studd, J. (2008). Testosterone for low libido in postmenopausal women\n              not taking estrogen. New England Journal of Medicine, 359, 2005\u20132017.\n              doi:10.1056\/NEJMoa0707302","DOI":"10.1056\/NEJMoa0707302"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Davis, S.R., & Wahlin-Jacobsen, S. (2015). Testosterone in\n              women\u2014The clinical significance. Lancet: Diabetes and Endocrinology, 3, 980\u2013992.\n              doi:10.1016\/s2213-8587(15)00284-3","DOI":"10.1016\/S2213-8587(15)00284-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Fernandes, T., Costa-Paiva, L.H., & Pinto-Neto, A.M. (2014).\n              Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual\n              function in postmenopausal women: A randomized controlled trial. Journal of Sexual\n              Medicine, 11, 1262\u20131270. doi:10.1111\/jsm.12473","DOI":"10.1111\/jsm.12473"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Kallak, T.K., Baumgart, J., G\u00f6ransson, E., Nilsson, K., Poromaa,\n              I.S., & Stavreus-Evers, A. (2014). Aromatase inhibitors affect vaginal\n              proliferation and steroid hormone receptors. Menopause, 21, 383\u2013390.\n              doi:10.1097\/GME.0b013e31829e41df","DOI":"10.1097\/GME.0b013e31829e41df"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Kallak, T.K., Baumgart, J., Nilsson, K., Akerud, H., Poromaa,\n              I.S., & Stavreus-Evers, A. (2015). Vaginal gene expression during treatment with\n              aromatase inhibitors. Clinical Breast Cancer, 15, 527\u2013535.\n              doi:10.1016\/j.clbc.2015.06.012","DOI":"10.1016\/j.clbc.2015.06.012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Krapf, J.M., Belkin, Z., Dreher, F., & Goldstein, A.T.\n              (2015). Current and emerging treatment options for vulvovaginal atrophy. In A.M.\n              Farage, W.K. Miller, N. Fugate Woods, & I.H. Maibach (Eds.), Skin, mucosa and\n              menopause: Management of clinical issues (pp. 229\u2013235). Berlin, Germany: Springer\n              Berlin Heidelberg.","DOI":"10.1007\/978-3-662-44080-3_18"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Krychman, M.L., & Katz, A. (2012). Breast cancer and\n              sexuality: Multi-modal treatment options. Journal of Sexual Medicine, 9, 5\u201313.\n              doi:10.1111\/j.1743-6109.2011.02566.x","DOI":"10.1111\/j.1743-6109.2011.02566.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kyvernitakis, I., Ziller, V., Hars, O., Bauer, M., Kalder, M.,\n              & Hadji, P. (2014). Prevalence of menopausal symptoms and their influence on\n              adherence in women with breast cancer. Climacteric, 17, 252\u2013259.\n              doi:10.3109\/13697137.2013.819327","DOI":"10.3109\/13697137.2013.819327"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Lester, J., Pahouja, G., Andersen, B., & Lustberg, M.\n              (2015). Atrophic vaginitis in breast cancer survivors: A difficult survivorship issue.\n              Journal of Personalized Medicine, 5, 50\u201366. doi:10.3390\/jpm5020050","DOI":"10.3390\/jpm5020050"},{"key":"16","unstructured":"National Comprehensive Cancer Network. (2015). NCCN Clinical\n              Guidelines in Oncology: Survivorship [v.2.2015]. Retrieved from\n              http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/survivorship.pdf"},{"key":"17","unstructured":"National Comprehensive Cancer Network. (2016). NCCN Clinical\n              Practice Guidelines in Oncology: Breast cancer [v.1.2016]. Retrieved from\n              https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Regan, M.M., Price, K.N., Giobbie-Hurder, A., Thurlimann, B.,\n              & Gelber, R.D. (2011). Interpreting Breast International Group (BIG) 1\u201398: A\n              randomized, double-blind, phase III trial comparing letrozole and tamoxifen as\n              adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive,\n              early breast cancer. Breast Cancer Research, 13, 209. doi:10.1186\/bcr2837","DOI":"10.1186\/bcr2837"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Schover, L.R., Baum, G.P., Fuson, L.A., Brewster, A., &\n              Melhem-Bertrandt, A. (2014). Sexual problems during the first 2 years of adjuvant\n              treatment with aromatase inhibitors. Journal of Sexual Medicine, 11, 3102\u20133111.\n              doi:10.1111\/jsm.12684","DOI":"10.1111\/jsm.12684"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Somboonporn, W., Davis, S., Seif, M.W., & Bell, R. (2005).\n              Testosterone for peri- and postmenopausal women. Cochrane Database of Systematic\n              Reviews, 4, CD004509. doi:10.1002\/14651858.CD004509.pub2","DOI":"10.1002\/14651858.CD004509.pub2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Wierman, M.E., Arlt, W., Basson, R., Davis, S.R., Miller, K.K.,\n              Murad, M.H., . . . Santoro, N. (2014). Androgen therapy in women: A reappraisal: An\n              Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and\n              Metabolism, 99, 3489\u20133510. doi:10.1210\/jc.2014-2260","DOI":"10.1210\/jc.2014-2260"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Witherby, S., Johnson, J., Demers, L., Mount, S., Littenberg,\n              B., Maclean, C.D., . . . Muss, H. (2011). Topical testosterone for breast cancer\n              patients with vaginal atrophy related to aromatase inhibitors: A phase I\/II study.\n              Oncologist, 16, 424\u2013431. doi:10.1634\/theoncologist.2010-0435","DOI":"10.1634\/theoncologist.2010-0435"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/44\/3\/vaginal-testosterone-management-aromatase-inhibitor-related-sexual-dysfunction-integrative","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:06Z","timestamp":1763754726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/44\/3\/vaginal-testosterone-management-aromatase-inhibitor-related-sexual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1188\/17.onf.296-301","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"value":"0190-535X","type":"print"},{"value":"1538-0688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,1]]}}}